Journal of Korean Biological Nursing Science

  • 제12권1호
  • /
  • Pages.63-72
  • /
  • 2010
  • /
  • 2383-6415(pISSN)
  • /
  • 2383-6423(eISSN)
한국기초간호학회 (Korean society of Biological Nursing Science)
권호 표지

폐경기 여성의 랄록시펜과 혈중 지질에 관한 체계적 문헌고찰

Raloxifene and Lipid Profiles in Postmenopausal Women: A Systematic Review

  • 유지수 (연세대학교 간호대학 임상간호과학과, 간호정책연구소, 생행동연구센터) ;
  • 안지현 (연세대학교 간호대학 임상간호과학과) ;
  • 김두리 (연세대학교 간호대학 임상간호과학과) ;
  • 추상희 (연세대학교 간호대학 임상간호과학과, 간호정책연구소, 생행동연구센터)
  • Yoo, Ji-Soo (Department of Clinical Nursing Science, College of Nursing, Nursing Policy Research Institute, Biobehavioral Research Center, Yonsei University) ;
  • An, Ji-Hyoun (Department of Clinical Nursing Science, College of Nursing, Yonsei University) ;
  • Kim, Doo-Ree (Department of Clinical Nursing Science, College of Nursing, Yonsei University) ;
  • Chu, Sang-Hui (Department of Clinical Nursing Science, College of Nursing, Nursing Policy Research Institute, Biobehavioral Research Center, Yonsei University)
  • 투고 : 2010.03.03
  • 심사 : 2010.04.06
  • 발행 : 2010.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The purpose of this study is to assess the effects of raloxifene in prevention of cardiovascular disease in postmenopausal women. Methods: A systematic literature review was conducted. Data sources: The existing literature from 1986 to 2009 was searched electronically using the data base of Medline with the key words of hypertension, obesity, diabetes, cholesterol, lipid, myocardial infarction, coronary events with combination of raloxifene. Study selection: The criteria for inclusion in the review were 1) an randomized clinical trial (RCT), 2) postmenopausal women, 3) English or Korean language. Finally, 15 articles were included in the review. Data extraction: Findings from the studies were organized according to the results of lipid profile changes by two authors. Results: Among 15 articles, 12 studies reported the beneficial effects of raloxifene on LDL cholesterol and 9 studies on total cholesterol in the postmenopausal women. Conclusion: The consistent results on reduction of LDL cholesterol and total cholesterol in raloxifene using postmenopausal women were confirmed. However, the effect of raloxifene on other components of lipid profile and endothelial function were still remaining controversial.

키워드

참고문헌

  1. Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association, 291, 1701-1712. https://doi.org/10.1001/jama.291.14.1701
  2. Barrett-Connor, E., Ensrud, K. E., Harper, K., Mason, T. M., Sashegyi, A., Krueger, K. A., et al. (2003). Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clinical Therapeutics, 25, 919-930. https://doi.org/10.1016/S0149-2918(03)80114-5
  3. Brussaard, H. E., Gevers, L. J., Frolich, M., Kluft, C., & Krans, H. M. (1997). Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia, 40, 843-849. https://doi.org/10.1007/s001250050758
  4. Chu, S. H., Lee, M. K., Kowalski, J., Beck, J., & Schwertz, D. (2008). Effect of estrogen on ovariectomy-induced obesity in rats. Journal of Korean Biological Nursing Science, 10, 80-87.
  5. Colacurci, N., Manzella, D., Fornaro, F., Carbonella, M., & Paolisso, G. (2003). Endothelial function and menopause: Effects of raloxifene administration. The Journal of Clinical Endocrinology & Metabolism, 88, 2135-2140. https://doi.org/10.1210/jc.2002-021557
  6. Collins, P., Mosca, L., Geiger, M. J., Grady, D., Kornitzer, M., Amewou- Atisso, M. G., et al. (2009). Effets of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for the Heart trial: Results of subgroup analyses by age and other factors. Circulation, 119, 922-930. https://doi.org/10.1161/CIRCULATIONAHA.108.817577
  7. Dias, A. R. Jr., Melo, R. N., Gebara, O. C., D'Amico, E. A., Nussbacher, A., Halbe, H. W., et al. (2005). Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric, 8, 63-70. https://doi.org/10.1080/13697130500042581
  8. Duvernoy, C. S., Kulkarni, P. M., Dowsett, S. A., & Keech, C. A. (2005). Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: Incidence, patient characteristics, and effect of raloxifene. Menopause, 12, 444-452. https://doi.org/10.1097/01.GME.0000151653.02620.89
  9. Engin-Ustun, Y., Ustun, Y., Meydanli, M. M., & Kafkasli, A. (2006). Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: A randomized, placebo-controlled clinical trial. Gynecological Endocrinology, 22, 676-679. https://doi.org/10.1080/09513590601069470
  10. Ettinger, B., Black, D. M., Mitkma, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. The Journal of the American Medical Association, 282, 637-645. https://doi.org/10.1001/jama.282.7.637
  11. Grady, D., Herrington, D., Bittner, V., Blumenlhal, R., Davidson, M., Hlatky, M., et al. (2002). Cardiovascular disease outcomes during 6.8 years of hormones therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). The Journal of the American Medical Association, 288, 49-57. https://doi.org/10.1001/jama.288.1.49
  12. Griffiths, K. A., Sader, M. A., Skilton, M. R., Harmer, J. A., & Celermajer, D. S. (2003). Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. Journal of the American College of Cardiology, 42, 698-704. https://doi.org/10.1016/S0735-1097(03)00776-9
  13. Hernandez, E., Valera, R., Alonzo, E., Bajares-Lilue, M., Carlini, R., Capriles, F., et al. (2003). Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International, 63, 2269-2274. https://doi.org/10.1046/j.1523-1755.2003.00005.x
  14. Hyung, H. K. & Kim, H. S. (2008). The effect of brisk walking exercise program on body composition, blood pressure, blood glucose and blood lipid for middle-aged women with obesity. Journal of Korean Biological Nursing Science, 10, 62-68.
  15. Iwamoto, J., Sato, Y., Uzawa, M., Takeda, T., & Matsumoto, H. (2008). Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Medical Journal, 49, 119-128. https://doi.org/10.3349/ymj.2008.49.1.119
  16. Kung, A. W., Chao, H. T., Huang, K. E., Need, A. G., Taechakraichana, N., Loh, F. H., et al. (2003). Efficacy and safety of raloxifene 60 milligrams/ day in postmeno-pausal Asian women. The Journal of Clinical Endocrinology &Metabolism, 88, 3130-3136. https://doi.org/10.1210/jc.2002-021855
  17. Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. The British Medical Journal, 339, b2700. https://doi.org/10.1136/bmj.b2700
  18. Ministry of Health and Welfare and Korea Institute for Health and Social Affairs. (2005). The Third Korea National Health and Nutrition Examination Survey. Unpublished Report.
  19. Mosca, L., Grady, D., Barrett-Connor, E., Collins, P., Wenger, N., Abramson, B. L., et al. (2009). Effect of raloxifen on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke, 40, 147- 155. https://doi.org/10.1161/STROKEAHA.108.518621
  20. Nanetti, L., Camilletti, A., Francucci, C. M., Vignini, A., Raffaelli, F., Mazzanti, L., et al. (2008). Role of raloxifene on platelet metabolism and plasma lipids. European Journal of Clinical Investigation, 38, 117-125. https://doi.org/10.1111/j.1365-2362.2007.01905.x
  21. Nickelsen, T., Creatsas, G., Rechberger, T., Depypere, H., Erenus, M., Quail, D., et al. (2001). Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: Results from the Euralox 1 study. Climacteric, 4, 320-331. https://doi.org/10.1080/cmt.4.4.320.331
  22. Oh, E. K., Choi, H., Lee, C. M., Cho, Y. K., Kim, B. R., Ko, J. K., et al. (2006). A comparion of the effects of raloxifene and estrogen therapy on lipid profile and bone mineral density in postmenopausal women. Journal of Korean Postmenopause, 12, 19-27.
  23. Reid, I. R., Eastell, R., Fogelman, I., Adachi, J. D., Rosen, A., Netelenbos, C., et al. (2004). A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Archives of Internal Medicine, 164, 871-879. https://doi.org/10.1001/archinte.164.8.871
  24. Regitz-Zagrosek, V., Wintermantel, T. M., & Schubert, C. (2007). Estrogens and SERMs in coronary heart disease. Current Opinion in Pharmacology, 7, 130-139. https://doi.org/10.1016/j.coph.2006.10.009
  25. Simoncini, T., Genazzani, A. R., & Liao, J. K. (2002). Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation, 105, 1368-1373. https://doi.org/10.1161/hc1102.105267
  26. Song, E. K., Yeom, J. H., Shin, H. T., Kim, S. H., Shin, W. G., & Oh, J. M. (2006). Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy. Journal of Clinical Pharmacy and Therapeutics, 31, 421-427. https://doi.org/10.1111/j.1365-2710.2006.00753.x
  27. Vogelvang, T. E., Mijatovic, V., Kenemans, P., Teerlink, T., & van der Mooren, M. J. (2004). HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertility and Sterility, 82, 1540-1549. https://doi.org/10.1016/j.fertnstert.2004.05.093
  28. Walsh, B. W., Kuller, L. H., Wild , R. A., Paul, S., Farmer, M., Lawrence, J. B., et al. (1998). Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. The Journal of the American Medical Association, 279, 1445-1451. https://doi.org/10.1001/jama.279.18.1445
  29. Yildiz, M. F., Kumru, S., Godekmerdan, A., & Kutlu, S. (2005). Effects of raloxifene, hormone therapy, and soy isoflavone on serum highsensitive C-reactive protein in postmenopausal women. International Journal of Gynecology &Obstetrics, 90, 128-133. https://doi.org/10.1016/j.ijgo.2005.05.005
  30. Zeng, S., Wu, Y., Zhang, Z., Yang, X., Hui, Y., Zhang, Y., et al. (2003). Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: A randomized clinical trial in Beijing. Chinese Medical Journal, 116, 1127-1133.